Search

Your search keyword '"Valovirta E"' showing total 685 results

Search Constraints

Start Over You searched for: Author "Valovirta E" Remove constraint Author: "Valovirta E"
685 results on '"Valovirta E"'

Search Results

1. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

2. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

3. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

4. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

5. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

6. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

7. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

10. The ARIA-MeDALL hypothesis

11. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

12. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study

13. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project)

14. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

15. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

16. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

17. Work productivity in rhinitis using cell phones: The MASK pilot study

18. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

19. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

20. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

21. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

22. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

23. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

24. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

26. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus

27. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®

28. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

29. The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

30. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

31. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

33. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

34. Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing

35. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

36. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

37. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

38. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

39. Treatment of allergic rhinitis during and outside the pollen season using mobile technology : A MASK study

42. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

43. International consensus on (ICON) pediatric asthma

47. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper

50. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’

Catalog

Books, media, physical & digital resources